Thursday, June 8, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Professor of Oncology
Medical Oncology Chair
Lausanne University Hospital
Lausanne, Switzerland
Professor and Head, Clinical Research
Gustave Roussy Cancer Center
Chair, EORTC Scientific Chairs Council
Villejuif, France
Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
Executive Director
Medical Oncology Research
MD Anderson Cancer Network
Center Clinical Medical Director
Clinical Center for Targeted Therapy
The University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™
This educational activity is intended for an international audience of non-US and non-UK oncology specialists, pulmonologists, and pathologists.
The goal of this activity is for learners to be better able to identify and manage patients with RET-altered non-small cell lung cancer (NSCLC).
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Professor of Oncology
Medical Oncology Chair
Lausanne University Hospital
Lausanne, Switzerland
Professor and Head, Clinical Research
Gustave Roussy Cancer Center
Chair, EORTC Scientific Chairs Council
Villejuif, France
Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
Executive Director
Medical Oncology Research
MD Anderson Cancer Network
Center Clinical Medical Director
Clinical Center for Targeted Therapy
The University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of
continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the
valid credit period that
is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in
your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as
the certificates from the
CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME Released: 11/21/2022
Valid for credit through: 11/21/2023
processing....
All sections of this activity are required for credit.
The goal of this activity is for learners to be better able to identify and manage patients with RET-altered non-small cell lung cancer (NSCLC).
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
